Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00385710
• Date of registration: 10/10/2006
• Prospective Registration: Yes
• Primary sponsor: Nantes University Hospital
• Public title: Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
• Scientific title: Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy
• Date of first enrolment: November 2006
• Target sample size: 28
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00385710
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
• Phase: Phase 2

Countries of recruitment

France

Contacts

• Name: Pascal Derkinderen
• Affiliation: Nantes University Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with possible or probable PSP

- from 45 to 75 year of age



Age minimum: 45 Years
Age maximum: 75 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Progressive Supranuclear Palsy

Intervention(s)

Drug: Placebo

Drug: valproic acid

Primary Outcome(s)

PSPRS score (specific score for PSP) [Time Frame: This score will be measured every three months during the two-year follow up of the study]

Secondary Outcome(s)

Neuropsychological evaluation [Time Frame: inclusion, one year and two years follow up]

Secondary ID(s)

05/10-H

Source(s) of Monetary Support

Please refer to primary and secondary sponsors